GO:0002474 antigen processing and presentation of peptide antigen via MHC class I: Immune Surveillance Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002474 describes the biological process in which an antigen-presenting cell expresses a peptide antigen on its surface in association with a classical MHC class I protein complex.
• The pathway is constitutively active in most nucleated cells and is essential for CD8+ cytotoxic T cell recognition of infected or transformed cells.
• IFN-gamma is a master cytokine that upregulates nearly every component of the MHC class I antigen processing and presentation machinery.
• Tumors evade immune destruction by suppressing MHC class I expression or antigen presentation, a mechanism linked to hypoxia, epigenetic dysregulation, and splicing changes.
• Pathogens such as Chikungunya virus can directly disrupt MHC class I antigen presentation through viral nonstructural proteins.
• CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools to dissect the causal roles of genes in this pathway.
Description
Antigen processing and presentation of peptide antigen via MHC class I (GO:0002474) is the biological process by which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with a classical MHC class I protein complex. This pathway allows the immune system to monitor the intracellular environment and detect infected or malignant cells. It is fundamental to CD8+ cytotoxic T cell-mediated immunity and is a central focus in cancer immunology, virology, and vaccine development. The process involves proteasomal degradation of cytosolic proteins, peptide transport into the endoplasmic reticulum, loading onto MHC class I molecules, and trafficking to the plasma membrane. Dysregulation of this pathway is a common mechanism of immune evasion in cancer and is targeted by viral proteins. Understanding the molecular players and regulatory mechanisms is essential for developing immunotherapies and vaccines.
antigen processing and presentation of peptide antigen via MHC class I At A Glance
| GO ID | GO:0002474 |
|---|---|
| GO term | antigen processing and presentation of peptide antigen via MHC class I |
| Ontology | biological_process |
| Synonym | peptide antigen processing and presentation via MHC class I |
| Major function | Surface presentation of intracellular peptides to CD8+ T cells |
| Key cytokine regulator | IFN-gamma |
| Cellular location | Cytosol, endoplasmic reticulum, Golgi, plasma membrane |
| Disease relevance | Cancer immune evasion, viral infection, autoimmunity |
What Is GO:0002474?
GO:0002474 is defined as the process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. The term specifically refers to classical class I molecules and encompasses the steps of peptide generation, transport, loading, and surface presentation.
Why Is antigen processing and presentation of peptide antigen via MHC class I Important in Cell Biology?
This process is a cornerstone of adaptive immunity, enabling the immune system to detect and eliminate cells that are infected or have become cancerous. Its dysregulation is a hallmark of tumor immune evasion and is exploited by numerous viruses, making it a critical target for immunotherapy and vaccine design.
• Enables CD8+ cytotoxic T cells to recognize and kill infected or transformed cells.
• Constitutive in most nucleated cells, providing broad immune surveillance.
• IFN-gamma strongly upregulates MHC class I antigen processing and presentation.
• Tumors frequently downregulate this pathway to escape immune detection.
• Hypoxia in the tumor microenvironment suppresses MHC-I expression and antigen presentation.
• Pharmacologic modulation of RNA splicing can enhance anti-tumor immunity by restoring antigen presentation.
• Loss of histone methyltransferase WHSC1 dampens MHC-I antigen presentation and impairs IFN-gamma-stimulated antitumor immunity.
• Chikungunya virus nonstructural protein 2 disrupts MHC-I antigen presentation.
• Dendritic cell-targeted vaccines aim to harness this pathway for protective immunity.
• Surface emergence and persistence of MHC class I free heavy chains may influence immune recognition.
What Happens During antigen processing and presentation of peptide antigen via MHC class I?
Peptide Generation by the Proteasome
In simple terms: Proteins inside the cell are chopped into small pieces by a molecular shredder called the proteasome.
Cytosolic proteins, including viral and tumor antigens, are degraded by the proteasome into short peptides. IFN-gamma upregulates immunoproteasome subunits, enhancing the generation of peptides optimal for MHC class I binding.
Peptide Transport into the Endoplasmic Reticulum
In simple terms: The chopped peptides are pumped into a cellular compartment called the endoplasmic reticulum.
The transporter associated with antigen processing (TAP) translocates peptides from the cytosol into the endoplasmic reticulum (ER). IFN-gamma increases TAP expression, facilitating peptide supply for MHC class I loading.
Peptide Loading onto MHC Class I
In simple terms: In the endoplasmic reticulum, peptides are loaded onto MHC class I molecules like a key into a lock.
The peptide loading complex, comprising TAP, tapasin, ERp57, and calreticulin, facilitates the assembly of MHC class I heavy chain with beta-2-microglobulin and the loading of high-affinity peptides. IFN-gamma upregulates these components to enhance presentation.
Trafficking and Surface Presentation
In simple terms: The loaded MHC class I molecules travel to the cell surface to display the peptide to immune cells.
Peptide-MHC class I complexes are transported through the Golgi to the plasma membrane, where they are presented to CD8+ T cells. Surface emergence and persistence of MHC class I free heavy chains can also occur and may modulate immune recognition.
Key Genes Involved in GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
The following genes encode core components of the MHC class I antigen processing and presentation pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HLA-A | Classical MHC class I heavy chain | Peptide presentation to CD8+ T cells |
| HLA-B | Classical MHC class I heavy chain | Peptide presentation to CD8+ T cells |
| HLA-C | Classical MHC class I heavy chain | Peptide presentation to CD8+ T cells |
| B2M | Beta-2-microglobulin, light chain of MHC class I | Required for MHC class I surface expression |
| TAP1 | Peptide transporter subunit | Transports peptides into ER |
| TAP2 | Peptide transporter subunit | Transports peptides into ER |
| PSMB8 | Immunoproteasome subunit | Generates peptides for MHC class I |
| PSMB9 | Immunoproteasome subunit | Generates peptides for MHC class I |
| PSMB10 | Immunoproteasome subunit | Generates peptides for MHC class I |
| TAPBP | Tapasin, peptide loading complex | Facilitates peptide loading onto MHC class I |
| CALR | Calreticulin, peptide loading complex | Assists MHC class I folding |
| PDIA3 | ERp57, peptide loading complex | Assists MHC class I folding |
| NLRC5 | Transcriptional regulator of MHC class I genes | Regulates MHC class I expression |
| IRF1 | IFN-gamma-inducible transcription factor | Upregulates MHC class I pathway genes |
| WHSC1 | Histone methyltransferase | Loss dampens MHC-I antigen presentation |
| ERAP1 | Aminopeptidase | Trims peptides for MHC class I |
| ERAP2 | Aminopeptidase | Trims peptides for MHC class I |
How Is antigen processing and presentation of peptide antigen via MHC class I Regulated?
The pathway is regulated at multiple levels. IFN-gamma is the principal cytokine that upregulates MHC class I antigen processing and presentation by inducing the expression of genes such as HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, PSMB8, PSMB9, and NLRC5. Hypoxia in the tumor microenvironment suppresses MHC-I expression and antigen presentation, promoting immune evasion. Pharmacologic modulation of RNA splicing can enhance anti-tumor immunity by altering the splicing of immune-related genes. Loss of the histone methyltransferase WHSC1 dampens MHC-I antigen presentation and impairs IFN-gamma-stimulated antitumor immunity. Viral proteins, such as Chikungunya virus nonstructural protein 2, can disrupt MHC-I antigen presentation.
antigen processing and presentation of peptide antigen via MHC class I and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| B2M | Cancer immune evasion | B2M knockout tumor cell lines |
| WHSC1 | Impaired antitumor immunity | WHSC1 knockout or knockdown models |
| HLA-A | Viral infection, autoimmunity | HLA-A point mutation or knockout |
| TAP1 | Cancer, viral evasion | TAP1 knockout cell lines |
| NLRC5 | Cancer immune evasion | NLRC5 overexpression or knockout |
Cancer Immune Evasion
Tumors often downregulate MHC class I antigen processing and presentation to escape CD8+ T cell recognition. Hypoxia in the tumor microenvironment suppresses MHC-I expression and antigen presentation. Loss of WHSC1 dampens MHC-I antigen presentation and impairs IFN-gamma-stimulated antitumor immunity. Pharmacologic modulation of RNA splicing can restore antigen presentation and enhance anti-tumor immunity.
Viral Infection
Viruses have evolved mechanisms to disrupt MHC class I antigen presentation. Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2. This allows the virus to evade CD8+ T cell responses.
Autoimmunity and Hair Follicle Immune Privilege
Collapse of hair follicle immune privilege, which involves MHC class I antigen presentation, is implicated in alopecia areata. This highlights the role of this pathway in autoimmune conditions.
From antigen processing and presentation of peptide antigen via MHC class I-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate MHC class I surface expression? | CRISPR knockout in tumor cell lines followed by flow cytometry |
| Does a specific point mutation in HLA-A affect peptide binding? | CRISPR point mutation knock-in in HLA-A |
| Can overexpression of NLRC5 restore antigen presentation? | NLRC5 overexpression in MHC-I-low tumor cells |
| What is the role of WHSC1 in IFN-gamma-stimulated antigen presentation? | WHSC1 knockout or knockdown |
| How does hypoxia affect MHC-I antigen presentation? | Hypoxia chamber experiments with tumor cells |
| Can splicing modulators enhance antigen presentation? | Pharmacologic splicing modulation in tumor cells |
How to Study the antigen processing and presentation of peptide antigen via MHC class I Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface MHC class I expression | Quantify antigen presentation |
| Mass spectrometry | Peptide repertoire bound to MHC class I | Identify presented antigens |
| CRISPR screening | Genes regulating MHC class I presentation | Discover immune evasion pathways |
| RNA-seq | Expression of MHC class I pathway genes | Assess transcriptional regulation |
| Western blot | Protein levels of pathway components | Validate knockout or overexpression |
| Immunofluorescence | Subcellular localization of MHC class I | Study trafficking |
| Tetramer staining | Antigen-specific T cell responses | Measure T cell activation |
Flow Cytometry
Flow cytometry is used to measure surface MHC class I expression on cells. It can quantify the percentage of cells presenting specific peptides using tetramers.
Immunoprecipitation and Mass Spectrometry
Immunoprecipitation of MHC class I molecules followed by mass spectrometry identifies the repertoire of peptides presented on the cell surface, providing insights into antigen processing.
CRISPR Screening
Genome-wide CRISPR screens can identify genes that regulate MHC class I surface expression or antigen presentation, as demonstrated in studies of immune evasion.
RNA Sequencing
RNA-seq measures the expression of MHC class I pathway genes and can reveal splicing changes that affect antigen presentation.
How CRISPR Can Be Used to Study GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
Knockout
CRISPR knockout of genes such as B2M, TAP1, or WHSC1 can abolish or reduce MHC class I antigen presentation, providing causal evidence for their roles. Knockout cell lines are valuable for studying immune evasion mechanisms.
Point Mutation
CRISPR point mutation can introduce specific amino acid changes in MHC class I heavy chains or pathway components to dissect functional domains, such as peptide binding pockets or interaction interfaces.
Knock-in
Knock-in of tagged MHC class I molecules or pathway components allows for tracking and purification, facilitating biochemical and imaging studies.
Overexpression
Overexpression of transcriptional regulators like NLRC5 or IRF1 can enhance MHC class I antigen presentation, potentially overcoming tumor immune evasion.
How EDITGENE Supports antigen processing and presentation of peptide antigen via MHC class I Research
Researchers studying antigen processing and presentation of peptide antigen via MHC class I-related genes often need to determine whether a candidate gene is causally involved in regulating this pathway. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for antigen processing and presentation of peptide antigen via MHC class I research.
Frequently Asked Questions About antigen processing and presentation of peptide antigen via MHC class I
What is antigen processing and presentation of peptide antigen via MHC class I?
It is the biological process (GO:0002474) in which an antigen-presenting cell expresses a peptide antigen on its surface in association with a classical MHC class I protein complex.
What genes are involved in antigen processing and presentation of peptide antigen via MHC class I?
Key genes include HLA-A, HLA-B, HLA-C, B2M, TAP1, TAP2, PSMB8, PSMB9, PSMB10, TAPBP, CALR, PDIA3, NLRC5, IRF1, and WHSC1.
How does IFN-gamma regulate MHC class I antigen presentation?
IFN-gamma upregulates the expression of MHC class I heavy chains, beta-2-microglobulin, TAP, and immunoproteasome subunits, enhancing peptide generation and presentation.
What is the role of MHC class I antigen presentation in cancer?
Tumors often downregulate this pathway to evade CD8+ T cell recognition; hypoxia and loss of WHSC1 are mechanisms of suppression.
How do viruses evade MHC class I antigen presentation?
Viruses such as Chikungunya virus disrupt MHC-I antigen presentation via nonstructural protein 2.
What experimental models are used to study MHC class I antigen presentation?
CRISPR knockout, point mutation, knock-in, and overexpression cell models, as well as CRISPR screening, are commonly used.
What is the role of WHSC1 in antigen presentation?
Loss of WHSC1 dampens MHC-I antigen presentation and impairs IFN-gamma-stimulated antitumor immunity.
Can splicing modulators enhance antigen presentation?
Pharmacologic modulation of RNA splicing can enhance anti-tumor immunity by restoring antigen presentation.
What is the significance of MHC class I free heavy chains?
Surface emergence and persistence of MHC class I free heavy chains may modulate immune recognition.
How is MHC class I antigen presentation linked to autoimmunity?
Collapse of hair follicle immune privilege, involving MHC class I antigen presentation, is implicated in alopecia areata.
Conclusion
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I is a central pathway in immune surveillance and a key target in cancer and viral immunity. Understanding its regulation and dysregulation provides opportunities for therapeutic intervention. EDITGENE offers advanced CRISPR services to study this pathway and accelerate discoveries.
References
- 1. Zhou F. 2009. Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation.. Int Rev Immunol 28(3-4):239-60 PMID: 19811323
- 2. Bertolini M et al.. 2020. Hair follicle immune privilege and its collapse in alopecia areata.. Exp Dermatol 29(8):703-725 PMID: 32682334
- 3. Estephan H et al.. 2025. Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation.. EMBO J 44(3):903-922 PMID: 39753950
- 4. Lu SX et al.. 2021. Pharmacologic modulation of RNA splicing enhances anti-tumor immunity.. Cell 184(15):4032-4047.e31 PMID: 34171309
- 5. Ren J et al.. 2022. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated antitumor immunity.. J Clin Invest 132(8) PMID: 35230972
- 6. Ware BC et al.. 2024. Chikungunya virus infection disrupts MHC-I antigen presentation via nonstructural protein 2.. PLoS Pathog 20(3):e1011794 PMID: 38483968
- 7. Cohn L et al.. 2014. Dendritic cell-targeted vaccines.. Front Immunol 5:255 PMID: 24910635
- 8. Ruggiero FM et al.. 2025. Surface emergence and persistence of MHC class I free heavy chains.. J Biol Chem 301(11):110799 PMID: 41067637
